Edwards Lifesciences Corporation

EW Healthcare Medical Devices

Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS fell 26.3%, free cash flow grew 142.8% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.

86.60 1.50 −1.70%
Market cap
$50.8B
P/E
49.8×
Fwd P/E
30.7×
Dividend yield
—
F-score
5/9
Altman Z
11.54
Beneish M
−2.48
Dividend safety
n/a

Edwards Lifesciences Corporation (EW) EV/FCF

Alert me on EV/FCF

As of 16 October 2026, Edwards Lifesciences Corporation (EW) trades at a EV/FCF of 33.4×. Over the past ten years it has ranged from 13.4× (January 2015) to 224× (April 2024); the current reading is higher than 7% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 35.9× (77.51%)
FY2024 160× 121.18%
FY2023 72.1× 48.99%
FY2022 48.4× (15.65%)
FY2021 57.4× (35.10%)
FY2020 88.5× 65.77%
FY2019 53.4× 13.22%
FY2018 47.1× 66.12%
FY2017 28.4× (31.10%)
FY2016 41.2× 8.33%

Quarterly newest first

Period EV/FCF Change
Jun 2026 35.0× (15.61%)
Mar 2026 41.4× 15.50%
Dec 2025 35.9× (35.14%)
Sep 2025 55.3× (28.30%)
42 more quarters

Against its own ten years

Low 13.4× High 224×
Ten-year median 51.4×
Current reading's percentile 3

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on EW